528882-12-4

Basic information

• Product Name: 3H-1,3,4-Benzotriazepine-3-acetic acid, 5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-1,2-dihydro-2-oxo-
• CAS NO: 528882-12-4
• Molecular Formula: C22H29N3O4
• Molecular Weight: 399.49
• Mol File: 528882-12-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3H-1,3,4-Benzotriazepine-3-acetic acid, 5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-1,2-dihydro-2-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-1,3,4-Benzotriazepine-3-acetic acid, 5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-1,2-dihydro-2-oxo-(528882-12-4)
• EPA Substance Registry System: 3H-1,3,4-Benzotriazepine-3-acetic acid, 5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-1,2-dihydro-2-oxo-(528882-12-4)

Safety Data

• Hazardous Substances Data: 528882-12-4(Hazardous Substances Data)

Upstream product

• 5469-26-1 1-Bromopinacolon 
• 3432-87-9 (2-aminophenyl)cyclohexylmethanone 
• 528882-08-8 (N'-((2-amino-phenyl)-cyclohexyl-methylene)-hydrazino)acetic acid ethyl ester 
• 528882-09-9 (5-cyclohexyl-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetic acid ethyl ester 
• 528882-11-3 (5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetic acid ethyl ester 

Downstream Products

• 528882-69-1 (3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-acetic acid 
• 528883-32-1 3-(3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-propionic acid 
• 528882-83-9 (3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenylsulfanyl)-acetic acid 
• 528884-14-2 ((3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-methyl-amino)-acetic acid 
• 799560-71-7 (3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-benzenesulfonyl)-acetic acid 
• 528883-16-1 (3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenoxy)-acetic acid 
• 528883-11-6 (tert-butoxycarbonyl-(3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-amino)-acetic acid 
• 528882-60-2 2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-N-(3-(2H-tetrazol-5-yl)-phenyl)-acetamide 
• 528885-34-9 3'-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-biphenyl-3-carboxylic acid 
• 528884-39-1 4-(3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-thiazole-2-carboxylic acid 
• 528885-22-5 2-(3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-oxazole-4-carboxylic acid 
• 528885-24-7 5-(3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-furan-2-carboxylic acid 
• 528885-52-1 (2-(3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-pyrrol-1-yl)-acetic acid 
• 528883-55-8 (6-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-indol-1-yl)-acetic acid 

Relevant articles and documents

Optimization of 1,3,4-benzotriazepine-based CCK2 antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion

Starting from a novel, achiral 1,3,4-benzotriazepine-based CCK2 receptor antagonist, a process of optimization has afforded further compounds of this type that maintain the nanomolar affinity for recombinant, human CCK2 receptors and high selectivity over

1, 3, 4-BENZOTRIAZEPIN-2-ONE SALTS AND THEIR USE AS CCK RECEPTOR LIGANDS

This invention relates to pharmaceutically acceptable salts of compounds of formula (I) wherein: W is N or N+-O-; R2 is an optionally substituted C1 to C18 hydrocarbyl group wherein up to three C atoms may optionally be replaced by N, O and/or S atoms. R3 is -(CR11R12)m-X-(CR13R14)p-R9; m is 0, 1, 2, 3 or 4; p is 0, 1 or 2; X is a bond, -CR15=CR16-, -C≡C-, C(O)NH, NHC(O), C(O)NMe, NMeC(O), C(O)O, NHC(O)NH, NHC(O)O, OC(O)NH, NH, O, CO, SO2, SO2NH, C(O)NHNH, R9 is H ; C1 to C6 alkyl ; or phenyl, naphthyl, pyridyl, benzimidazolyl, indazolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolinyl, isoindolinyl, indolyl, isoindolyl or 2-pyridonyl substituted with -L-Q. R4 is an optionally substituted C1 to C18 hydrocarbyl group wherein up to three C atoms may optionally be replaced by N, O and/or S atoms ; and Such salts are useful, for example, for the treatment of gastrin related disorders.